EQL PHARMA AB (7JK) — Capital Reinvestment Ratio
Latest as of December 2025:
0.88x
EQL PHARMA AB (7JK) has a Capital Reinvestment Ratio of 0.88x as of December 2025, meaning it reinvests 1% of its operating cash flow (€13.44 Million) in capital expenditures (€11.87 Million). See 7JK FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.88x
Capex / Operating Cash Flow
Operating Cash Flow
€13.44 Million
EUR
Capital Expenditures
€11.87 Million
EUR
Data as of
Dec 2025
Most recent filing
EQL PHARMA AB Capital Reinvestment Ratio (2022–2023)
This chart tracks EQL PHARMA AB's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for EQL PHARMA AB (2022–2023)
Year-by-year Capital Reinvestment Ratio for EQL PHARMA AB from 2022 to 2023. For live market cap and broader valuation context, see EQL PHARMA AB (7JK) total market value.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.74x | €27.62 Million | €20.51 Million | ▲ +40.6% |
| 2022 | 0.53x | €41.83 Million | €22.09 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow